Literature DB >> 1837236

The role of arginine residues in interleukin 1 receptor binding.

V B Nanduri1, J D Hulmes, Y C Pan, P L Kilian, A S Stern.   

Abstract

Interleukin 1 (IL-1) is a family of polypeptide cytokines that plays an essential role in modulating immune and inflammatory responses. IL-1 activity is mediated by either of two distinct proteins, IL-1 alpha or IL-1 beta, both of which bind to the same receptor found on T-lymphocytes, fibroblasts and endothelial cells (Type 1 receptor). The effect of specific chemical modification of recombinant IL-1 alpha and IL-1 beta on receptor binding was examined. Modification of the proteins with phenylglyoxal, an arginine-specific reagent, resulted in the loss of Type 1 IL-1 receptor binding activity. The stoichiometry of this modification revealed that a single arginine in either IL-1 alpha or IL-1 beta is responsible for the loss of activity. Cyanogen bromide cleavage of phenylglyoxal modified IL-1 alpha and IL-1 beta, followed by sequencing of the peptides, revealed that arginine-12 in IL-1 alpha and arginine-4 in IL-1 beta, which occupy the same topology in the respective crystallographic structures, are the target of phenylglyoxal. These results suggest that an arginine residue plays an important role in ligand-receptor interaction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1837236     DOI: 10.1016/0167-4838(91)90437-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Differential sensitivity to Arg side chain modification of IL-1 beta binding to type I and type II receptors.

Authors:  Z Tömösközi; G Bugovics; S Koncz; P Arányi
Journal:  Agents Actions       Date:  1994-03

2.  Arg-27, Arg-127 and Arg-155 in the beta-trefoil protein barley alpha-amylase/subtilisin inhibitor are interface residues in the complex with barley alpha-amylase 2.

Authors:  K W Rodenburg; E Várallyay; I Svendsen; B Svensson
Journal:  Biochem J       Date:  1995-08-01       Impact factor: 3.857

3.  Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation.

Authors:  Paul Proost; Tamara Loos; Anneleen Mortier; Evemie Schutyser; Mieke Gouwy; Samuel Noppen; Chris Dillen; Isabelle Ronsse; René Conings; Sofie Struyf; Ghislain Opdenakker; Prabhat C Maudgal; Jo Van Damme
Journal:  J Exp Med       Date:  2008-08-18       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.